Insulet (NSDQ:PODD) said today it will present new clinical data on its artificial pancreas algorithm, new product pipeline and evidence from studies of its OmniPod system.
The news is set to be presented this week at the American Diabetes Association’s 76th Scientific Sessions in New Orleans, the company said.
“We are pleased to present several new studies on the benefits of our Omnipod System in type 1 and type 2 diabetes patients for whom effective treatments are important given the enormous daily burden associated with managing their disease. We are deeply committed to improving the lives of people with diabetes by offering advanced education and resources to our growing Podder community. We also remain focused on innovation through our Digital Insulet strategy, which will increase patient mobile connectivity and ultimately help deliver our first product with artificial pancreas functionality,” CEO Patrick Sullivan said in a press release.
Insulet said its 1st artificial pancreas will operate on its Omnipod platform coupled with Dexcom CGM technology, and will be powered by an algorithm it licensed from Mode AGC in February this year.
The Billerica, Mass.-based company said a feasibility study using the algorithm and a next-gen Omnipod prototype is currently underway, and it expects to begin on-body trials later this year.
In May, Insulet said it launched a new online platform for diabetes patients who use its Omnipod insulin management system, alongside a new mobile app and new branding for the device.
Insulet said it’s hoping that the new brand, app and social media presence will increase community among Omnipod customers and attract new patients to the therapy.
The post Insulet updates on artificial pancreas, pipeline products appeared first on MassDevice.